ROLE OF PROBIOTICS IN GASTROINTESTINAL TRACT DISEASES: INFLAMMATORY BOWEL DISEASE AND NECROTIZING ENTEROCOLITIS

Authors

  • SHATAKSHI SHUKLA Department of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
  • SALONI VERMA Department of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
  • REKHA SHARMA Department of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
  • ANKITA KUMARI Department of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
  • RAHUL ADLINGE Department of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

DOI:

https://doi.org/10.22159/ijcpr.2021v13i1.40813

Keywords:

Inflammatory Bowel Diseases, Necrotizing Enterocolitis, Gastrointestinal tract

Abstract

Bacterial microflora which is present in gastrointestinal tract cause various disorders. Probiotics provides beneficial effects in gut related disease. Previously probiotics are used as alternative medicine but now entering in mainstream medicine. Probiotics help in restoring normal bacterial microflora and regulate the gastrointestinal tract functioning through different mechanisms. There are only few evidences available which show potential benefits of probiotics. The efficiency of probiotics used as a single strain or multiple formulation is tested in various diseases such oral health, diabetes, multiple sclerosis, inflammatory bowel disease, necrotising enterocolitis and many more. The purpose of this paper is to focus on diseases related to gastrointestinal tract including inflammatory bowel disease and necrotising enterocolitis based on the literature review available and propose future perspective to reduce the translocation of bacterial microflora in gastrointestinal tract and reducing subsequent inflammation of gut. Keywords were searched in goggle scholar, academic research, PubMed and Embase databases.

References

1. AP Bai, Q Ouyang. Probiotics and inflammatory bowel diseases. Postgrad Med J 2006;82:376–82.
2. Qingdong Guan. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019;16:7247238.
3. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 2004;4:5.
4. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 2005;11:833-9.
5. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462-4.
6. Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, et al. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol 2013;11:982-7.
7. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997;25:653-8.
8. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. Multicenter randomizedcontrolled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13:135-42.
9. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
10. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7.
11. Simren M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:218-27.
12. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127-35.
13. Sondergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebocontrolled trial. Scand J Gastroenterol 2011;46:663-72.
14. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
15. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-84.
16. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 2012;18:2067-75.
17. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-7.
18. Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011;20:397-401.
19. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-83.
20. Dolin BJ. Effects of a proprietary bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655-9.
21. Shin MS, Han SK, Ji AR, Kim KS, Lee WK. Isolation and characterization of bacteriocin-producing bacteria from the gastrointestinal tract of broiler chickens for probiotic use. J Appl Microbiol 2008;105:2203-12.
22. Petricevic L, Witt A. The role of lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG 2008;115:1369-74.
23. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleocaecal resection. Inflamm Bowel Dis 2007;13:135-42.
24. Eckmann L, Jung HC, Schurer Maly C. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology 1993;105:1689–97.
25. Neish AS, Gewirtz AT, Zeng H. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560–3.
26. Vavricka SR, Musch MW, Chang JE. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004;127:1401–9.
27. Neudeck BL, Loeb JM, Faith NG. Lactobacillus casei alters hPEPT1-mediated glycylsarcosine uptake in caco-2 cells. J Nutr 2004;134:1120–3.
28. Borruel N, Carol M, Casellas F. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659–64.
29. Andreakos E, Foxwell B, Feldmann M. Is targeting toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokinedriven inflammation? Immunol Rev 2004;202:250–65.
30. Nencioni A, Wesselborg S, Brossart P. Role of peroxisome proliferatoractivated receptor gamma and its ligands in the control of immune responses. Crit Rev Immunol 2003;23:1–13.
31. Dubuquoy L, Jansson EA, Deeb S. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265–76.
32. Kelly D, Campbell JI, King TP. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARgamma and RelA. Nat Immunol 2004;5:104–12.
33. Kim SH, Yang SJ, Koo HC. Inhibitory activity of Bifidobacterium longum HY8001 against vero cytotoxin of escherichia coli O157:H7. J Food Prot 2001;64:1667–73.
34. Martin RJ, Fanaroff AA, Walsh MC. eds. Caplan M. Neonatal necrotizing enterocolitis. In: Fanaroff and Martin's Neonatal-Perinatal Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 94.
35. Greenberg JM, Haberman B, Narendran V, Nathan AT, Schibler K. Neonatal morbidities of prenatal origin. In: Resnik R, Lockwood CJ, Moore TR, Greene MF, Copel JA, Silver RM. eds. Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2019. p. 73.
36. Kliegman RM, St Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Seed PC. The microbiome and pediatric health. In: Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020. p. 196.
37. Sawh SC, Deshpande S, Jansen S, Reynaert CJ, Jones PM PeerJ. Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis. 2016;4:e2429.
38. Garrison D, Barile D, Mills DA. A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract. Adv Nutr 2012;3:415S–21S.
39. Costeloe K, Hardy P, Juszczak E, Wilks M, Millar MR. Probiotics in preterm infants study collaborative group. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet 2016;387:649-60.
40. Dani C, Coviello CC, Corsini II, Arena F, Antonelli A, Rossolini GM. Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. AJP Rep 2016;6:e25–9.
41. US Food and Drug Administration. FDA Investigates Presence of Mucormycosis-causing Mold in Infant and Children’s Probiotic Supplement; 2016.
42. Underwood MA. Impact of probiotics on necrotizing enterocolitis. Semin Perinatol 2017;41:41–51.
43. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881–4.
44. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, et al. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radical Biol Med 2009;47:1205–11.
45. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560–3.
46. Rivera Chavez F, Lopez CA, Baumler AJ. Oxygen as a driver of gut dysbiosis. Free Radical Biol Med 2017;105:93–101.
47. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 2012;180:626–35.
48. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008;46(Suppl 2):S87–91, S144-51.

Published

2021-01-16

How to Cite

SHUKLA, S., S. VERMA, R. SHARMA, A. KUMARI, and R. ADLINGE. “ROLE OF PROBIOTICS IN GASTROINTESTINAL TRACT DISEASES: INFLAMMATORY BOWEL DISEASE AND NECROTIZING ENTEROCOLITIS”. International Journal of Current Pharmaceutical Research, vol. 13, no. 1, Jan. 2021, pp. 1-6, doi:10.22159/ijcpr.2021v13i1.40813.

Issue

Section

Review Article(s)